On August 28, CANSINOBIO fell 5.4% in regular trading, trading at HKD 33.38/share, with turnover of HKD 78.42 million. The decline marks a second consecutive session of pullback following a period of significant gains.

Despite posting positive interim results on August 27 — with H1 revenue rising 43.81% year-over-year to RMB 550 million, overseas revenue surging over 4,700% to RMB 150 million, and net loss narrowing 94.65% to just RMB 720,000 — the stock continued to face selling pressure. The company had previously rallied sharply after Moderna's mRNA cancer vaccine achieved Phase 3 clinical success on August 19, followed by CANSINOBIO's announcement of a strategic cooperation framework agreement with deepGeneAI to co-develop personalized mRNA therapeutic cancer vaccines on August 25. These catalysts drove the H-share up over 16% on August 26 and the A-share to accumulate gains exceeding 30% over three trading days, creating substantial profit-taking pressure that began materializing on August 27 with a 5% decline and extended into today's session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)